SoftBank Eyes $20 Billion Bond Sale to Refinance OpenAI Loan 
Trian Drops Wendy’s Take-Private Bid Plans, Shares Plunge 14% 
Toyota Global Sales Fall as China Demand Slumps 
Amazon Secures 200 MW Wind Power Deals in Sweden 
Itochu Offers $1.56 Billion to Privatize Dentsu Soken 
Meta Agrees to $18 Billion Settlement, Tightens Teen Social Media Rules 
BNP Paribas, KB Kookmin Eye $2 Billion Techcombank Stake 
Mercer International Stock Surges 45% on C$20 Million Canada Funding 
BofA Names ASML Top Semiconductor Equipment Pick on Growth, Valuation 
Nvidia Reportedly Eyes $13 Billion Hugging Face Acquisition 
Shein Hong Kong IPO to Raise $1.7 Billion at $26.5 Billion Valuation 
Yindjibarndi Appeals Fortescue Mining Compensation Ruling 
OpenAI AI Agent Swarm Behind Hugging Face Hack 
HP Stock Drops 9% Despite Q3 Earnings Beat and Raised 2026 Outlook 
Salesforce Shares Surge as AI Demand Powers Q2 Earnings Beat 
PayPal Shares Sink as $50 Billion Takeover Bid Collapses 
Trump Administration Plans New Drug Pricing Deals With Biotech Firms 
 for treatment of cutaneous T-cell lymphoma (CTCL) - EconoTimes)
Add as a preferred source on Google
La Chaux-de-Fonds, Switzerland, April 09, 2018 -- Rhizen Pharmaceuticals S.A., today announced that the U.S. Food and Drug Administration (FDA) has granted orphan-drug designation for the active moiety of Tenalisib (RP6530), the Company’s highly selective and orally active dual PI3K delta/gamma inhibitor, for treatment of cutaneous T-cell lymphoma (CTCL).
“We are pleased to receive US FDA orphan-drug designations for the active moiety of Tenalisib (RP6530) for the treatment of peripheral and cutaneous T-cell Lymphoma (PTCL and CTCL), and we look forward to advancing the drug into further development for treatment of T-cell lymphoma,” said Swaroop Vakkalanka, Ph.D., Founder & President of Rhizen Pharmaceuticals S.A.
About FDA Orphan-Drug Designation:
Orphan-Drug Designation is granted to a drug or biological product intended to treat a rare disease in the United States. A number of incentives are provided for an orphan-drug such as 7-year marketing exclusivity, tax credits for clinical development costs, exemption/waiver of application (filing) fees and assistance from the FDA Office of Orphan Products Development (OOPD) during the development process.
About Tenalisib (RP6530):
Tenalisib (RP6530) is a highly selective and orally active dual PI3K delta/gamma inhibitor with efficient translation of activity through enzyme, cell, and whole blood-based studies. Besides inhibiting growth of immortalized cancerous cell lines and primary patient leukemic/lymphoma cells, RP6530 plays a significant role in modulation of tumor microenvironment at clinically achievable concentrations. In preclinical studies, RP6530 reprograms macrophages from an immunosuppressive M2-like phenotype (pro-tumor) to an inflammatory M1-like state (anti-tumor), which can potentially enhance the activity of checkpoint inhibitors or overcome resistance to these drugs. Tenalisib obtained US FDA Fast Track Designation for treatment of peripheral T-cell lymphoma (PTCL) in addition to Orphan-Drug Designations for treatment of peripheral and cutaneous T-cell lymphoma (PTCL and CTCL).
About Rhizen Pharmaceuticals S.A.:
Rhizen Pharmaceuticals is an innovative, clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for the treatment of cancer, immune and metabolic disorders. Since its establishment in 2008, Rhizen has created a diverse pipeline of proprietary drug candidates targeting several cancers and immune associated cellular pathways. Rhizen is headquartered in La-Chaux-de-Fonds, Switzerland. For additional information, please visit Rhizen’s website, www.rhizen.com.
Contact: Kumar V. Penmetsa, Ph.D. Executive Vice President, Corporate Development Rhizen Pharmaceuticals S.A. Telephone: +1-267-207-5707 Email: [email protected]
